Leerink Partnrs Has Negative Outlook of MLTX FY2025 Earnings

MoonLake Immunotherapeutics (NASDAQ:MLTX) – Stock analysts at Leerink Partnrs dropped their FY2025 EPS estimates for MoonLake Immunotherapeutics in a note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($3.22) per share for the year, down from their prior estimate of ($3.06). The consensus estimate for MoonLake Immunotherapeutics’ current full-year earnings is ($1.79) per share. Leerink Partnrs also issued estimates for MoonLake Immunotherapeutics’ FY2026 earnings at ($4.26) EPS, FY2027 earnings at ($4.76) EPS and FY2028 earnings at $1.81 EPS.

Other research analysts have also recently issued research reports about the company. Wedbush reiterated an “outperform” rating and set a $73.00 price objective (down previously from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Friday, January 10th. Finally, The Goldman Sachs Group raised shares of MoonLake Immunotherapeutics from a “neutral” rating to a “buy” rating and increased their price objective for the company from $62.00 to $82.00 in a research report on Friday, January 17th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, MoonLake Immunotherapeutics has an average rating of “Buy” and a consensus price target of $84.29.

MoonLake Immunotherapeutics Stock Down 2.2 %

Shares of MLTX opened at $44.07 on Monday. The stock has a market cap of $2.82 billion, a P/E ratio of -34.16 and a beta of 1.28. The business’s 50 day moving average price is $49.69 and its 200-day moving average price is $49.07. MoonLake Immunotherapeutics has a 52 week low of $37.55 and a 52 week high of $64.98.

Institutional Investors Weigh In On MoonLake Immunotherapeutics

Several large investors have recently bought and sold shares of the business. US Bancorp DE purchased a new stake in MoonLake Immunotherapeutics during the 3rd quarter valued at $44,000. Barclays PLC increased its position in MoonLake Immunotherapeutics by 1,269.2% during the third quarter. Barclays PLC now owns 5,641 shares of the company’s stock valued at $283,000 after acquiring an additional 5,229 shares during the last quarter. PNC Financial Services Group Inc. lifted its holdings in MoonLake Immunotherapeutics by 3.9% in the fourth quarter. PNC Financial Services Group Inc. now owns 8,500 shares of the company’s stock valued at $460,000 after acquiring an additional 320 shares during the period. Handelsbanken Fonder AB lifted its holdings in MoonLake Immunotherapeutics by 26.2% in the third quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock valued at $655,000 after acquiring an additional 2,700 shares during the period. Finally, AlphaCentric Advisors LLC bought a new stake in shares of MoonLake Immunotherapeutics during the 3rd quarter valued at about $706,000. 93.85% of the stock is currently owned by institutional investors.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.